Dopamine D3 receptor antagonists: A patent review (2007-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 3, 2013, Pages 363-381

  Micheli, Fabrizio ^a   Heidbreder, Christian ^b  

^a Aptuit Inc   (United States)

^b RECKITT BENCKISER   (United Kingdom)

Author keywords

7TM; Addiction; D3; Dopamine; Impulse control disorders; Receptor; Schizophrenia; Selective antagonist

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; A 437203; AMIDE; ANTIPARKINSON AGENT; AVE 5997; CLOZAPINE; DIZOCILPINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GSK 598809; HALOPERIDOL; MORPHOLINE DERIVATIVE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; NAFADOTRIDE; NEUROLEPTIC AGENT; PLACEBO; RACLOPRIDE; RISPERIDONE; S 33084; UNCLASSIFIED DRUG;

ALCOHOLISM; BINDING AFFINITY; BRAIN DEPTH STIMULATION; CONCENTRATION RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; GOVERNMENT; HUMAN; IMPULSE CONTROL DISORDER; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; PATENT; PREMATURE EJACULATION; PSYCHOPHARMACOTHERAPY; RENAL PROTECTION; REVIEW; REWARD; SCHIZOPHRENIA; SINGLE DRUG DOSE; TOBACCO DEPENDENCE; UNIVERSITY;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; COGNITION; CUES; DOPAMINE ANTAGONISTS; EJACULATION; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; KIDNEY DISEASES; LIMBIC SYSTEM; MALE; MOTIVATION; PATENTS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, DOPAMINE D3; RECURRENCE; REWARD; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84874027543     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.757593     Document Type: Review

References (206)

1. Sokoloff P, Giros B, Martres M-P, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146-51
2. Sokoloff P, Dias J, Le Foll B, et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006;5:25-43
3. Micheli F, Heidbreder C. Selective dopamine D3 receptor antagonists ; 1997 - 2007: A decade of progress. Expert Opin Ther Patents 2008 ;18:821-40
4. Micheli F. Recent advances in the development of dopamine D3 receptor antagonists: A medicinal chemistry perspective. ChemMedChem 2011;6:1152-62
5. Hackling AE, Stark H. Dopamine D3 receptor ligands with antagonist properties. ChemBioChem 2002;3:946-61
6. Heidler P, Zohrabi-Kalantari V, Calmels T, et al. Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1- yl]butyl}carboxamides. Bioorg Med Chem 2005;13:2009-14
7. Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. Pharmacol Exp Ther 2000;294:1154-65
8. Pryde DC, Dalvie D, Hu Q, et al. Aldehyde oxidase: An enzyme of emerging importance in drug discovery. J Med Chem 2010;53:8441-60
9. Newman AH, Blaylock BL, Nader MA, et al. Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochem Pharmacol 2012;84(7):882-90. Available from: http://dx.doi.org/10.1016/j. bcp.2012.06.023
10. Bonanomi G, Di Fabio R, Fazzolari E, et al. Glaxo Group Ltd. WO2007022933 ; 2007
11. Capelli AM, Fazzolari E, Micheli F, et al. Glaxo Group Ltd. WO2007022936 ; 2007
12. Gentile G, Hamprecht D, Micheli F, et al. Glaxo Group Ltd. WO2007022935 ; 2007
13. Arista L, Checchia A, Gentile G, et al. Glaxo Group Ltd. WO2007022934 ; 2007
14. Bertani B, Micheli F, Pasquarello A, et al. Glaxo Group Ltd. WO2007113258 ; 2007
15. Bertani B, Bonanomi G, Capelli AM, et al. Glaxo Group Ltd. WO2007113232 ; 2007
16. Bertani B, Checchia A, Di Fabio R, et al. Glaxo Group Ltd. WO2007113260 ; 2007
17. Bertani B, Cardullo F, Dambruoso P, et al. Glaxo Group Ltd. WO2009043883 ; 2009
18. Bertani B, Cremonesi S, Fontana S, et al. Glaxo Group Ltd. WO2009043884 ; 2009
19. Bertani B, Di Fabio R, Micheli F, et al. Glaxo Group Ltd. WO2007125061 ; 2007
20. Anderton CL, Bacchi S, Beato S, et al. Glaxo Group Ltd. WO2008022994 ; 2008
21. Hamprecht D, Heidbreder C, Melotto S, et al. Glaxo Group Ltd. WO2007022980 ; 2007
22. Grandel R, Braje WM, Haupt A, et al. Abbott GmbH & Co. KG, Germany. WO2007118859; 2007
23. Braje W, Turner SC, Haupt A, et al. Abbott GmbH & Co. KG, Germany. WO2009056625; 2009
24. Turner SC, Haupt A, Braje W, et al. Abbott GmbH & Co. KG, Germany. WO2009056600; 2009
25. Grandel R, Braje WM, Haupt A, et al. Abbott GmbH & Co. KG, Germany. WO2007118900; 2007
26. Grandel R, Braje WM, Haupt A, et al. Abbott GmbH & Co. KG, Germany. WO2007118899; 2007
27. Gobbi L, Jaeschke G, Rodriguez Sarmiento RM, et al. F. Hoffmann-La Roche AG, Switz. US20100075979 ; 2010
28. Gobbi L, Jaeschke G, Rodriguez Sarmiento RM, et al. F. Hoffmann-La Roche AG, Switz. US20100075981 ; 2010
29. Prior KJ, Jaeschke G, Sarmiento RM, et al. F. Hoffmann-La Roche AG, Switz. US20100075985 ; 2010
30. Gobbi L, Jaeschke G, Luebbers T, et al. F. Hoffmann-La Roche AG, Switz. WO2007093540 ; 2007
31. Gobbi L, Jaeschke G, Luebbers T, et al. F. Hoffmann-La Roche AG, Switz. US20080103174 ; 2008
32. Gobbi L, Jaeschke G, Luebbers T, et al. F. Hoffmann-La Roche AG, Switz. WO2009013212 ; 2009
33. Gobbi L, Jaeschke G, Luebbers T, et al. F. Hoffmann-La Roche AG, Switz. WO2009019174 ; 2009
34. Gobbi L, Jaeschke G, Luebbers T, et al. F. Hoffmann-La Roche AG, Switz. WO2010031735 ; 2010
35. Gobbi L, Sarmiento RM, Wichmann J, et al. F. Hoffmann-La Roche AG, Switz. US20110313151 ; 2011
36. Gobbi L, Sarmiento RM, Wichmann J, et al. F. Hoffmann-La Roche AG, Switz. WO2012004206 ; 2012
37. Sarmiento RM, Wichmann J ; F. Hoffmann-La Roche AG, Switz. WO2012080149 ; 2012
38. Wager TT, Chandrasekaran RY, Butler TW ; Pfizer Products, Inc. WO2008026046 ; 2008
39. Capet M, Danvy D, Levoin N, et al. Bioprojet Fr. WO2007148208 ; 2007
40. Sokoloff P, Imbert T, Vergnes L, et al. Pierre Fabre Medicament, Fr. WO2008009741 ; 2008
41. Sokoloff P, Imbert T, Leriche L, et al. Pierre Fabre Medicament, Fr. WO2011027289 ; 2011
42. Sokoloff P, Imbert T, Leriche L, et al. Pierre Fabre Medicament, Fr. Demande. FR2949465 ; 2011
43. De Nanteuil G, Cimetiere B, Dekeyne A, et al. Les Laboratoires Servier, Fr. WO2011010014 ; 2011
44. Newman AH, Grundt P, Cyriac GC, et al. The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA. WO2008153573; 2008
45. Li J, Yang R, Song R, et al. Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China, Peop. Rep. China. WO2010040274; 2010
46. Wang S, Chen J, Collins G, et al. University of Michigan, USA. WO2010025235; 2010
47. Campiani G, Butini S, Fattorusso C, et al. Universita degli Studi di Siena, Italy. WO2008043839; 2008
48. Peters D, Roenn LC, Nielsen KS, et al. NeuroSearch A/S, Den. WO2009095438 ; 2009
49. Peters D, Roenn LC, Nielsen KS, et al. NeuroSearch A/S, Den. WO2009112568 ; 2011
50. Peters D, Roenn LC, Nielsen KS ; NeuroSearch A/S, Den. WO2010040808 ; 2010
51. Barta Szalai G, Agai Csongor E, Domany G, et al. Richter Gedeon Nyrt, Hung. WO2008125891 ; 2008
52. Barta Szalai G, Agai Csongor E, Domany G, et al. Richter Gedeon Nyrt, Hung. US20090143398 ; 2009
53. Newman AH, Beuming T, Banala AK, et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem 2012;55:6689-99
54. Diaz J, Pilon C, Le Foll B, et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 2000;20:8677-84
55. Gehlert DR. Quantitative autoradiography of Gpp(NH)p sensitive and insensitive [3H]quinpirole binding sites in the rat brain. Synapse 1993;14:113-20
56. Stanwood GD, Artymyshyn RP, Kung MP, et al. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: Evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 2000;295:1223-31
57. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 1998;800:269-74
58. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60-80
59. Landwehrmeyer B, Mengod G, Palacios JM. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 1993;18:187-92
60. Hall H, Halldin C, Dijkstra D, et al. Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907. Psychopharmacology (Berl) 1996;128:240-7
61. Herroelen L, De Backer JP, Wilczak N, et al. Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-npropyl-2-aminotetralin. Brain Res 1994;648:222-8
62. Murray AM, Ryoo HL, Gurevich E, et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994;91:11271-5
63. von Economo C, Koskinas GN. The cytoarchitectonics of the human cerebral cortex. Oxford University Press, London; 1929
64. Nimchinsky EA, Vogt BA, Morrison JH, et al. Spindle neurons of the human anterior cingulate cortex. J Comp Neurol 1995;355:27-37
65. Nimchinsky EA, Gilissen E, Allman JM, et al. A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci USA 1999;96:5268-73
66. Butti C, Santos M, Uppal N, et al. Von Economo neurons: Clinical and evolutionary perspectives. Cortex 2011; Epub ahead of print
67. Allman JM, Tetreault NA, Hakeem AY, et al. The von Economo neurons in the frontoinsular and anterior cingulate cortex. Ann NY Acad Sci 2011;1225:59-71
68. Allman JM, Tetreault NA, Hakeem AY, et al. The von Economo neurons in apes and humans. Am J Hum Biol 2011;23:5-21
69. Berthoz S, Armony JL, Blair RJ, et al. An fMRI study of intentional and unintentional (embarrassing) violations of social norms. Brain 2002;125:1696-708
70. Spence SA, Hunter MD, Farrow TF, et al. A cognitive neurobiological account of deception: Evidence from functional neuroimaging. Philos Trans R Soc Lond B Biol Sci 2004;359:1755-62
71. Naqvi NH, Rudrauf D, Damasio H, et al. Damage to the insula disrupts addiction to cigarette smoking. Science 2007;315:531-4
72. Mash DC. D3 receptor binding in human brain during cocaine overdose. Mol Psychiatry 1997;2:5-6
73. Mash DC, Staley JK. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 1999;877:507-22
74. Segal DM, Moraes CT, Mash DC. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997;45:335-9
75. Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996;16:6100-6
76. Le Foll B, Frances H, Diaz J, et al. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002;15:2016-26
77. Neisewander JL, Fuchs RA, Tran-Nguyen LT, et al. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine selfadministration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004;29:1479-87
78. Le Foll B, Diaz J, Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003;47:176-83
79. Le Foll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D3 receptor ligands. Mol Psychiatry 2003;8:225-30
80. Spangler R, Goddard NL, Avena NM, et al. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain Res Mol Brain Res 2003;111:74-83
81. Vengeliene V, Leonardi-Essmann F, Perreau-Lenz S, et al. The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse. FASEB J 2006;20:2223-33
82. Boileau I, Payer D, Houle S, et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: A positron emission tomography study. J Neurosci 2012;32:1353-9
83. Wilson AA, McCormick P, Kapur S, et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10bhexahydro-2H-naphtho[1,2-b][1,4] oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005;48:4153-60
84. Gallezot JD, Beaver JD, Gunn RN, et al. Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012;66:489-500
85. Ginovart N, Willeit M, Rusjan P, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-71
86. Graff-Guerrero A, Willeit M, Ginovart N, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 2008;29:400-10
87. Kiss B, Horti F, Bobok A. In vitro and in vivo comparison of [3H](+)-PHNO and [3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites. Synapse 2011;65:467-78
88. Narendran R, Slifstein M, Guillin O, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006;60:485-95
89. Narendran R, Frankle WG, Mason NS, et al. Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propylnorapomorphine: Preliminary evaluation and reproducibility studies. Synapse 2009;63:574-84
90. Rabiner EA, Laruelle M. Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 2010;13:289-90
91. Rabiner EA, Slifstein M, Nobrega J, et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 2009;63:782-93
92. Searle G, Beaver JD, Comley RA, et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010;68:392-9
93. Tziortzi AC, Searle GE, Tzimopoulou S, et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage 2011;54:264-77
94. Day M, Bain E, Marek G, et al. D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol 2010;13:291-2
95. Graff-Guerrero A, Redden L, Abi-Saab W, et al. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 2010;13:273-87
96. Heidbreder CA, Newman AH. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 2010;1187:4-34
97. Heidbreder CA, Gardner EL, Xi Z-X, et al. The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Rev 2005;49:77-105
98. Achat-Mendes C, Grundt P, Cao J, et al. Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: Studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 2010;334:556-65
99. Andreoli M, Tessari M, Pilla M, et al. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003;28:1272-80
100. Gal K, Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull 2003;61:595-601
101. Higley AE, Kiefer SW, Li X, et al. Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine- induced reinstatement of drug-seeking in rats. Eur J Pharmacol 2011;659:187-92
102. Higley AE, Spiller K, Grundt P, et al. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol 2011;25:263-73
103. Micheli F, Bonanomi G, Blaney FE, et al. 1,2,4-Triazol-3-yl- thiopropyltetrahydrobenzazepines: A series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 2007;50:5076-89
104. Orio L, Wee S, Newman AH, et al. The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol 2010;15:312-23
105. Peng XQ, Ashby CR Jr, Spiller K, et al. The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats. Neuropharmacology 2008;56:752-60
106. Ross JT, Corrigall WA, Heidbreder CA, et al. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007;559:173-9
107. Song R, Yang RF, Wu N, et al. YQA14: A novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 2012;17:259-73
108. Vorel SR, Ashby CR Jr, Paul M, et al. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002;22:9595-603
109. Xi ZX, Gardner EL. Pharmacological actions of NGB-2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 2007;13:240-59
110. Xi ZX, Gilbert JG, Pak AC, et al. Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost/ variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005;21:3427-38
111. Xi ZX, Newman AH, Gilbert JG, et al. The novel dopamine D3 receptor antagonist NGB-2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006;31:1393-405
112. Austin NE, Baldwin SJ, Cutler L, et al. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001;31:677-86
113. Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000;294:1154-65
114. Stemp G, Ashmeade T, Branch CL, et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl] cyclohexyl]-4-quinolinecarboxamide (SB-277011A): A potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 2000;43:1878-85
115. Thanos PK, Katana JM, Ashby CR Jr, et al. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 2005;81:190-7
116. Millan MJ, Mannoury la Cour C, Novi F, et al. S33138 [N-[4-[2-[(3aS,9bR)- 8-cyano-1,3a,4,9b-tetrahydro [1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl] phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 2008;324:587-99
117. Millan MJ, Svenningsson P, Ashby CR Jr, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro [1]-benzopyrano[3,4-c]pyrrol- 2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 2008;324:600-11
118. Millan MJ, Loiseau F, Dekeyne A, et al. S33138 (N-[4-[2-[(3aS,9bR)-8- cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl] phenylacetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008;324:1212-26
119. Rice OV, Patrick J, Schonhar CD, et al. The effects of the preferential dopamine D(3) receptor antagonist S33138 on ethanol binge-drinking in C57BL/6J mice. Synapse 2012;66(11):975-8
120. Pak AC, Ashby CR Jr, Heidbreder CA, et al. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006;9:585-602
121. Spiller K, Xi ZX, Peng XQ, et al. The selective dopamine D(3) receptor antagonists SB-277011A and NGB-2904 and the putative partial D(3) receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl.) 2008;196:533-42
122. Gilbert J. Proceedings of the 14th Annual Symposium of the International Cannabinoid Research Society (ICRS); 22 - 27 June 2004; Paestum (Italy)
123. Yuan J, Chen X, Brodbeck R, et al. NGB-2904 and NGB 2849: Two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 1998;8:2715-18
124. Grundt P, Carlson EE, Cao J, et al. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 2005;48:839-48
125. Ashby CR Jr, Paul M, Gardner EL, et al. Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003;48:154-6
126. Gyertyan I, Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport 2003;14:93-8
127. Macdonald GJ, Branch CL, Hadley MS, et al. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-Phenyl)carboxamido) cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (SB-414796): A potent and selective dopamine D3 receptor antagonist. J Med Chem 2003;46:4952-64
128. Rice OV, Gardner EL, Heidbreder CA, et al. The acute administration of the selective dopamine D(3) receptor antagonist SB-277011A reverses conditioned place aversion produced by naloxone precipitated withdrawal from acute morphine administration in rats. Synapse 2012;66:85-7
129. Swain SN, Beuk J, Heidbreder CA, Beninger RJ. Role of dopamine D(3) receptors in the expression of conditioned fear in rats. Eur J Pharmacol 2008;579:167-76
130. Di Ciano P, Underwood RJ, Hagan JJ, et al. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003;28:329-38
131. Di Ciano P. Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala. Behav Neurosci 2008;122:129-39
132. Cervo L, Cocco A, Petrella C, et al. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007;10:167-81
133. Gal K, Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 2006;81:63-70
134. Gilbert JG, Newman AH, Gardner EL, et al. Acute administration of SB-277011A, NGB-2904, or BP-897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: Role of dopamine D3 receptors. Synapse 2005;57:17-28
135. Campiani G, Butini S, Trotta F, et al. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003;46:3822-39
136. Khaled MA, Farid Araki K, Li B, et al. The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP-897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol 2010;13:181-90
137. Heidbreder CA, Andreoli M, Marcon C, et al. Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007;12:35-50
138. Epstein DH, Preston KL, Stewart J, et al. Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl.) 2006;189:1-16
139. Xi ZX, Gilbert J, Campos AC, et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl.) 2004;176:57-65
140. Mugnaini M, Iavarone L, Cavallini P, et al. Occupancy of brain dopamine D(3) receptors and drug craving: A translational approach. Neuropsychopharmacol 2012 ; [Epub ahead of print]
141. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: Neural and neurochemical substrates. Neurosci Biobehav Rev 2004;28:771-84
142. Sato K, Ueda H, Okumura F, et al. 6-OHDA-induced lesion of the nigrostriatal dopaminergic neurons potentiates the inhibitory effect of 7-OHDPAT, a selective D3 agonist, on acetylcholine release during striatal microdialysis in conscious rats. Brain Res 1994;655:233-6
143. Sigala S, Missale C, Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol 1997;336:107-12
144. Lacroix LP, Hows ME, Shah AJ, et al. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003;28:839-49
145. Lacroix LP, Ceolin L, Zocchi A, et al. Selective dopamine D(3) receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 2006;157:25-31
146. Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: A parallel neurochemical and behavioural analysis. J Neurochem 2007;100:1047-61
147. Laszy J, Laszlovszky I, Gyertyan I. Dopamine D3 receptor antagonists improve the learning performance of memory-impaired rats. Psychopharmacology (Berl.) 2005;179:567-75
148. Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 2010;13:1035-51
149. Watson DJ, Loiseau F, Ingallinesi M, et al. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: A key role for the prefrontal cortex. Neuropsychopharmacology 2012;37:770-86
150. Loiseau F, Millan MJ. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D(1) receptor agonists, but not of D(2) antagonists. Eur Neuropsychopharmacol 2009;19:23-33
151. Watson DJ, Marsden CA, Millan MJ, et al. Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 2012;15:471-84
152. Glickstein SB, Desteno DA, Hof PR, et al. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2005;15:1016-24
153. Micale V, Cristino L, Tamburella A, et al. Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res 2010;61:531-6
154. Xing B, Meng X, Wei S, et al. Influence of dopamine D3 receptor knockout on age-related decline of spatial memory. Neurosci Lett 2010;481:149-53
155. Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 1999;128:78-87
156. Moeller FG, Dougherty DM, Barratt ES, et al. Increased impulsivity in cocaine dependent subjects independent of antisocial personality disorder and aggression. Drug Alcohol Depend 2002;68:105-11
157. Petry NM. Substance abuse, pathological gambling, and impulsiveness. Drug Alcohol Depend 2001;63:29-38
158. Vuchinich RE, Simpson CA. Hyperbolic temporal discounting in social drinkers and problem drinkers. Exp Clin Psychopharmacol 1998;6:292-305
159. Madden GJ, Petry NM, Badger GJ, et al. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: Drug and monetary rewards. Exp Clin Psychopharmacol 1997;5:256-62
160. Leyton M, Boileau I, Benkelfat C, et al. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: A PET/[11C] raclopride study in healthy men. Neuropsychopharmacology 2002;27:1027-35
161. Thome J, Weijers HG, Wiesbeck GA, et al. Dopamine D3 receptor gene polymorphism and alcohol dependence: Relation to personality rating. Psychiatr Genet 1999;9:17-21
162. Meszaros K, Lenzinger E, Hornik K, et al. The Tridimensional Personality Questionnaire as a predictor of relapse in detoxified alcohol dependents. The European Fluvoxamine in Alcoholism Study Group. Alcohol Clin Exp Res 1999;23:483-6
163. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003;49:226-31
164. Vandenbergh DJ, O'Connor RJ, Grant MD, et al. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addict Biol 2007;12:106-16
165. Gurevich EV, Bordelon Y, Shapiro RM, et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997;54:225-32
166. Schwartz JC, Diaz J, Pilon C, et al. Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000;31:277-87
167. Mogenson GJ, Yang CR, Yim CY. Influence of dopamine on limbic inputs to the nucleus accumbens. Ann NY Acad Sci 1988;537:86-100
168. Meincke U, Morth D, Voss T, et al. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis-a longitudinal study. Eur Arch Psychiatry Clin Neurosci 2004;254:415-21
169. Zhang M, Ballard ME, Unger LV, et al. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav Brain Res 2007;182:1-11
170. Zhang M, Ballard ME, Kohlhaas KL, et al. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006;31:1382-92
171. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-19
172. Southam E, Lloyd A, Jennings CA, et al. Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain. Brain Res 2007;1149:50-7
173. Robertson GS, Lee CJ, Sridhar K, et al. Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004;20:3189-94
174. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27
175. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86-9
176. Dawson NM, Hamid EH, Egan MF, et al. Changes In the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001;39:70-81
177. Dubertret C, Gorwood P, Ades J, et al. Meta-analysis of Drd3 gene and schizophrenia: Ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 1998;81:318-22
178. Jonsson EG, Flyckt L, Burgert E, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: Association study and meta-analysis. Psychiatr Genet 2003;13:1-12
179. Serretti A, Lattuada E, Cusin C, et al. Dopamine D3 receptor-gene- notassociated-with-symptomatology-ofmajor-psychoses. Am J Med Genet 1999;88:476-80
180. Krebs MO, Sautel F, Bourdel MC, et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 1998;3:337-41
181. Ebstein RP, Macciardi F, Heresco-Levi U, et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47:6-16
182. Griffon N, Crocq MA, Pilon C, et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996;67:63-70
183. Nimgaonkar VL, Sanders AR, Ganguli R, et al. Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. Am J Med Genet 1996;67:505-14
184. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-19
185. Gourion D, Goldberger C, Leroy S, et al. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. Neuroreport 2005;16:1407-10
186. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-7
187. Silverdale MA, Nicholson SL, Ravenscroft P, et al. Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004;188:128-38
188. O'Connell DP, Vaughan CJ, Aherne AM, et al. Expression of the dopamine D3 receptor protein in the rat kidney. Hypertension 1998;32:886-95
189. Luippold G, Beilharz M, Wehrmann M, et al. Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2005;371:420-7
190. Gross ML, Koch A, Muhlbauer B, et al. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab Invest 2006;86:262-74
191. Kitrey ND, Clement P, Bernabe J, et al. Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience 2007;149:636-41
192. Clement P, Bernabe J, Denys P, et al. Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino) tetralin in anesthetized rats. Neuroscience 2007;145:605-10
193. Clement P, Pozzato C, Heidbreder C, et al. Delay of ejaculation induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. J Sex Med 2009;6:980-8
194. Gyertyan I, Saghy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007;572:171-4
195. Millan MJ, Gobert A, Newman-Tancredi A, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1048-62
196. Millan MJ, Dekeyne A, Rivet JM, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1063-73
197. Siuciak JA, Fujiwara RA. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl.) 2004;175:163-9
198. Chourbaji S, Brandwein C, Vogt MA, et al. Dopamine receptor 3 (D3) knockout mice show regular emotional behaviour. Pharmacol Res 2008;58:302-7
199. Martelle JL, Claytor R, Ross JT, et al. Effects of two novel D3-selective compounds, NGB-2904 [N-(4-(4-(2,3 dichlorophenyl)piperazin-1-yl)butyl)-9H- fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl)butyl)-4-(pyridin-2-yl) benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 2007;321:573-82
200. Thanos PK, Michaelides M, Ho CW, et al. The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav 2008;89:499-507
201. Nathan PJ, O'Neill BV, Mogg K, et al. The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. Int J Neuropsychopharmacol 2012;15:149-61
202. Mogg K, Bradley BP, O'Neill B, et al. Effect of dopamine D(3) receptor antagonism on approach responses to food cues in overweight and obese individuals. Behav Pharmacol 2012;23:603-8
203. Dodds CM, O'Neill B, Beaver J, et al. Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite 2012;27-33
204. Bocker A, Sasse BC, Nietert M, et al. GPCR targeted library design: Novel dopamine D3 receptor ligands. ChemMedChem 2007;2:1000-5
205. Pilla M, Perachon S, Sautel F, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999;400:371-5
206. Hackling A, Ghosh R, Perachon S, et al. N-(omega-(4-(2-methoxyphenyl) piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem 2003;46:3883-99